Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Chicmax is a prominent Chinese multi-brand beauty and personal care company that integrates advanced biotechnology into its skincare research and development. Established in 2002 and headquartered in Shanghai, the company operates a diverse portfolio of brands including Kans, One Leaf, and Baby Elephant, which cater to anti-aging, hydration, and pediatric skincare needs. Chicmax distinguishes itself through its dual-drive strategy, combining robust independent R&D capabilities with sophisticated multi-brand management. The company maintains state-of-the-art research centers in both China and Japan, focusing on proprietary ingredient innovation such as bio-fermentation and plant-based actives. As a publicly traded entity on the Hong Kong Stock Exchange, Chicmax continues to expand its footprint in the global cosmeceutical market by leveraging scientific rigor and consumer insights.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Chicmax.